An observational study in Coronary Artery Disease, sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.
Sponsored by Fondazione Ricerca e Innovazione Cardiovascolare ETS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To investigate whether pre-procedural OCT-derived de novo coronary lesion phenotype (lipid-rich, fibrotic, calcific; and ACS mechanisms such as plaque rupture/erosion/calcified nodule) is associated with clinical outcomes after DCB angioplasty.
PICCOLETO IX PHENO is an investigator-initiated, multicenter, international, ambispective (retrospective and prospective) cohort study enrolling patients who underwent DCB angioplasty for de novo coronary artery disease with preprocedural OCT assessment of the target segment. OCT images (baseline mandatory; post-preparation and post-PCI when available) and angiography will be analyzed by independent core laboratories; clinical events will be adjudicated by an independent committee. The primary endpoint is clinically-driven target lesion revascularization at 12 months; secondary endpoints include device-oriented composite endpoint (cardiac death, TLR, target-vessel MI), target vessel revascularization, MI endpoints, and mortality.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
This study's planned enrollment of 600 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Fondazione Ricerca e Innovazione Cardiovascolare ETS is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with chronic coronary syndrome or acute coronary syndrome who underwent drug-coated balloon angioplasty for de novo obstructive coronary artery disease with preprocedural optical coherence tomography assessment of the target segment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Clinically-driven Target Lesion Revascularization (TLR)
Any repeat revascularization (percutaneous or surgical) of the target lesion performed for recurrent symptoms or objective evidence of ischemia attributable to the target lesion.
Time frame: 12 months
Device-Oriented Composite Endpoint (DOCE)
Composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization.
Time frame: 12 months
Target Vessel Revascularization (TVR)
Any repeat revascularization (percutaneous or surgical) of the target vessel.
Time frame: 12 months
All-cause Mortality
Death from any cause during the study follow-up period.
Time frame: 12 months
Cardiac Death
Death attributed to cardiovascular causes, including death from unknown cause.
Time frame: 12 months
Target-Vessel Myocardial Infarction (TV-MI)
Myocardial infarction attributable to the target vessel based on clinical, electrocardiographic, and biomarker criteria according to the Fourth Universal Definition of Myocardial Infarction.
Time frame: 12 months
Any Myocardial Infarction
Any myocardial infarction (target-vessel or non-target-vessel) according to the Fourth Universal Definition of Myocardial Infarction.
Time frame: 12 months
No study locations are listed for this record.
Plan to share: Undecided — Individual participant data may be made available to qualified researchers upon reasonable request after study completion and primary publication, subject to appropriate data use agreements and ethics committee approval.
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Mar 2027, 14 months later.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 14 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Ricerca e Innovazione Cardiovascolare ETS